PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of viroljBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleVirology JournalJournal Front Page
 
Virol J. 2011; 8: 368.
Published online 2011 July 27. doi:  10.1186/1743-422X-8-368
PMCID: PMC3156777

An overview of Triple infection with Hepatitis B, C and D viruses

Abstract

Viral hepatitis is one of the major health problems worldwide, particularly in South East Asian countries including Pakistan where hepatitis C virus (HCV) and hepatitis B virus (HBV) infections are highly endemic. Hepatitis delta virus (HDV) is also not uncommon world-wide. HCV, HBV, and HDV share parallel routes of transmission due to which dual or triple viral infection can occur in a proportion of patients at the same time. HBV and HCV are important factors in the development of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). In addition to LC and HCC, chronic HDV infection also plays an important role in liver damage with oncogenic potential.

The current article reviews the available literature about the epidemiology, pathogenesis, transmission, symptoms, diagnosis, replication, disease outcome, treatment and preventive measures of triple hepatitis infection by using key words; epidemiology of triple infection, risk factors, awareness status, treatment and replication cycle in PubMed, PakMediNet, Directory of Open Access Journals (DOAJ) and Google Scholar. Total data from 74 different studies published from 1983 to 2010 on triple hepatitis infections were reviewed and included in this study. The present article briefly describes triple infection with HCV, HBV and HDV.

Keywords: viral hepatitis, HCV, HBV, HDV, liver cirrhosis, hepatocellular carcinoma

Introduction

Hepatitis is a Latin word which means inflammation of liver. At the present time viral hepatitis is a major health problem worldwide, particularly in Asian countries [1]. Hepatitis is caused by different hepatic viruses and it leads to liver related morbidity [2-4]. Mostly hepatic infection is caused by single hepatic virus but sometime infection with multiple viruses may occur and it leads to different management problems. These different problems include higher incidence of morbidity and mortality [5].

As hepatitis C virus (HCV), hepatitis B virus (HBV) and hepatitis D virus (HDV) are transmitted via similar routes that is through blood or blood products so as a result, dual infection and even triple infection can occur in some patients [1,6-10] at the same time. A condition in which all three viruses (Hepatitis B, C and D) occur together in the same patient is called Triple infection [1].

Viral hepatitis is one of the major health issues these days [11,12]. HBV is a partially double stranded, enveloped DNA virus that belongs to the Hepadnaviridae family and Orthohepadnavirus genus. Its size ranges from 40 to 42 nm, replicates in the liver and causes hepatic abnormalities [13,14]. It damages liver through immune mediated mechanisms [15,16]. HBV is the 9th leading cause of death worldwide. There are about 400 million people worldwide who are HCV carriers [17]. It causes cirrhosis, liver failure and hepatocellular carcinoma (HCC) [18]. Annually one million people die due to HBV [19,20]. It has worldwide distribution and is also well documented in Pakistan [21,22].

HCV is a single stranded RNA, enveloped virus that belongs to Flaviviridae family [23]. More than 170 million people are infected with HCV in the world [24]. Like HBV, it replicates in the liver and causes liver abnormalities. Like HBV, it also leads to many serious complications including cirrhosis, liver injury and hepatocellular carcinoma (HCC) [25,26]. These two (HBV and HCV) are the main causes of chronic hepatitis [2,4]. HBV and HCV infection are common in those areas where these two viruses are endemic [27-31].

Hepatitis D virus (HDV) or delta virus is a defective virus. It requires the help of another virus that is hepatitis B virus for its multiplication. It always occur with HBV either in the form of co-infection or super-infection. It is very rare but most severe form of the viral hepatitis [32]. This virus cannot replicate or multiply in the absence of HBV [9]. So we can say that HDV is the result of HBV [33,34]. Worldwide 15 million people positive for hepatitis B are also infected with hepatitis D [35]. Like HBV and HCV, it also plays a significant role in liver abnormalities. It also has oncogenic abnormalities [36,37].

Literature Search

Epidemiology of triple viral infection

Cases of triple viral infections and multiple viral infections had been reported from different regions of the world [5,10,38,39]. Mongolia is a country which is highly endemic for triple hepatitis viruses (with HBV, HCV, and HDV). Consequently many cases of triple infection are reported from here. It is also been reported that in Mongolia there is high prevalence of HBV, HCV and HDV [5,38,40-42]. There are also other regions of the world from where triple viral hepatitis infections had been reported including India and China [43,44]. Taiwan is another country which was previously reported as HBV and HCV endemic area but recent studies showed that now it is also endemic for HDV. Many cases of triple infection of hepatitis viruses are also reported from this region. Among the triple hepatitis patients in Taiwan, the prevalence of HBV is 12.6%, HCV is 41.6% and that of HDV is 15.3% [1]. Up to now, there is no report on triple infection caused by hepatitis viruses from Pakistani population [38].

Pathogenesis

There are many controversies about the role of triple hepatic infection in the pathogenesis of liver disease. It has been reported that triple viral infection does not cause the development of HCC but only one virus that dominate other two viruses in triple viral infection causes this condition of HCC [43].

Transmission routes

HBV, HCV and HDV viruses are not only biologically different but their life cycles and modes of gene expression are also totally different from each other. Despite of all these differences, they share same routes of transmission [45]. These three viruses (HBV, HCV, and HDV) are the major causes of chronic liver disease. All three viruses (HBV, HCV, and HDV) are transmitted due to direct or indirect exposure to infected blood or body fluids that contain infected blood. Common routes for transmission of these viruses are infected blood transfusion, contaminated syringes, injecting, tattoo and skin piercing with infected instruments, infected household contacts, through infected mother to her baby, by sexual contact with infected person, and via sharing of needles contaminated by infected drug users etc [46]. It is not unusual to find a patient who is co-infected with HBV and HCV or HBV and HDV or with all three viruses (HBV, HCV, and HDV) [1,5-8,47,48].

Symptoms

Viral hepatitis is of major concern as it leads to morbidity and mortality. Whatever its cause is, all types of viral hepatitis affect liver cells. As a result, many signs and symptoms of various types of hepatitis are almost similar and these are not specific to the viral agent that causes them. Most common symptoms are yellowed eyes or skin (jaundice), fever, fatigue, loss of appetite, joint pain, abdominal pain, diarrhea, nausea, vomiting, dark urine and flu-like symptoms. Some patients may experience few or no symptoms [49-52].

Diagnosis

Diagnosis of hepatic viral infection is carried out by studying biochemical, virological and histological parameters. Liver function tests (LFT) and serologic assays are also used for detection of antigens and antibodies. As all hepatitis viral infections have same sign and symptoms so it is very difficult to diagnose triple viral infection. A liver function test is available but the pattern of abnormality for acute infection is similar for all types of viral hepatitis. Individually each infection (HBV, HCV and HDV) is confirmed by the presence of the serum surface antigen, hepatitis B, C and D envelope antigen and specific antibodies to the hepatitis B, C and D core. Moreover polymerase chain reaction (PCR) and enzyme linked immunosorbant assay (ELISA) are also used for confirmation [53]. Diagnosis of HCV infection is done by detecting anti-HCV antibody by ELISA method or HCV RNA by PCR method in the serum. HDV is diagnosed by the presence of anti-HDV antibody in the serum using specific ELISA assay. Diagnosis of multiple hepatitis viral infections using one assay is not possible to date. It may be due to low level of awareness among physicians and availability of simple diagnostic tests. But recently scientists used a single integrated protein micro-array for diagnosing multiple viral infections. It can determine two viral antigens (HBsAg, HBeAg) and seven viral antibodies (HBsAb, HBcAb, HBeAb, HCVAb, HDVAb, HEVAb, HGVAb) of human hepatitis viruses in human sera just within 20 minutes [38,54]. However this is very expensive and available in developed countries only.

Replication status of viruses in triple infection

Although the replication pathway of HBV, HCV and HDV are different but one interesting virological aspect in case of triple infection is that up to what extent each virus affects the replication pathway of other virus and which one is responsible for the pathogenesis of liver disease. The reciprocal influence of HBV, HCV and HDV is still not clear [47,55]. In triple infection with HBV, HCV and HDV, there is interference between the viruses. In such situation one virus might suppresses the effect of others. As some studies have shown that HCV suppresses the effect of HBV and HDV and in some cases it causes sero-clearance of HBV antigens. Similarly there are studies which reported that HBV and HDV suppress HCV effect [48].

Several studies have shown that HDV act as a dominant virus in triple infection and it inhibits the replication of both HBV and HCV [47,48,56-59]. Some studies have also shown that HCV is cleared when patient is super-infected with HBV and HDV [60]. The reason for this could be the inhibition of markers required for their replication [47,58]. Actually large delta antigen of HDV inhibits the host DNA dependent RNA polymerase II which is involved in HBV replication [58,61]. However, some studies reported that HCV act as a dominant virus in triple infection. A study conducted on triple infection of HBV, HCV and HDV by Liaw and colleagues showed that newcomer virus suppress existent viruses [62]. Another study in Australia showed that in patients infected with HBV, HCV and HDV, replication of HBV is suppressed [63]. A study done by Mathurin showed that in Western countries dominant virus is HDV and there is no replication of HCV and HBV in patients with triple infection. Such discrepancies between the studies can be explained as the time of infection and host immune status are different in different parts of the world as a result of which different viruses are dominant in triple infection in different parts of the world [47].

Disease outcome

As in triple infection all the three viruses are present so scientists are of the view that there are more complications in the early appearance of this disease [64]. A study conducted by Liaw et al on the disease outcome of triple infection with HBV, HCV and HDV reported that this disease is more severe in the acute super-infection stage [62]. Other studies also suggested that infection with HBV, HCV and HDV increases the risk of fulminant hepatitis which is severe impairment of hepatic functions or severe necrosis of hepatocytes [65,66]. Patients with triple infection of HBV, HCV and HDV suffer from more severe liver lesions. They show a high tendency for cirrhosis. They also show increased risk for progression to HCC [63,67-69].

Treatment

Virological response in case of triple infection varies widely and show many different profiles. As a result of this, level of viruses varies during the therapy and follow-up period. For a proper treatment of triple infection, patient should be followed up yearly and the viral load should be determined which tells us which one virus is gone to be dominant and then we can treat it accordingly [70]. Patients with triple infection involving HBV, HCV and HDV show severe and progressive liver disease. Many studies have shown that when patients with triple infection are treated with interferon therapy, they show resistance to interferon therapy whereas patients having a single viral infection respond to his therapy [48]. Weltman et al., also reported that when seven patients having triple infection were treated with interferon-alpha, six show no response and there is only one patient who normalized serum alanine aminotransferase (ALT) during treatment. So they provide a proof that triple infection show less response to interferon therapy [63].

When patients with triple infection involving HBV, HCV and HDV are treated with lamivudine alone and lamivudine in combination with interferon, they have not shown positive results [71,72]. Another option for patients with triple infection involving HBV, HCV and HDV is liver transplantation. Risk of recurrence of HBV and HCV is decreased in transplanted liver which otherwise may occur due to viral interference phenomenon [73]. Treatment options for triple infection involving HBV, HCV and HDV are very limited. There is no optimal treatment for this up to now [73]. For selecting most appropriate antiviral treatment of triple infection, patient should be monitored carefully and virological assessment should be carried out to determine dominant virus.

Preventive measures

There are a lot of preventive measures which should be carried out in order to avoid development of triple infection. Some of these are [74]:

1. Screening of donated blood and plasma

2. Routine immunization for infants and high-risk individuals

3. Practicing safe sex

4. Cleaning up blood spills promptly with bleach

5. Avoiding sharing razors, syringes, tooth brushes, nail clippers, or needles, when getting a manicure, a tattoo, or having any body part pierced [74].

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MR searched the literature, organized the data. MR wrote the manuscript. HK and FK helped MR in literature review. MI revised the manuscript. All the authors read and approved the final version of the manuscript.

References

  • Lu SN, Chen TM, Lee CM, Wang JH, Tung HD, Wu JC. Molecular epidemiological and clinical aspects of hepatitis D virus in a unique triple hepatitis viruses (B, C, D) endemic community in Taiwan. J Med Virol. 2003;70:74–80. doi: 10.1002/jmv.10361. [PubMed] [Cross Ref]
  • World Health Organization. Hepatitis B Fact sheet no 204. 2000. http://who.int/mediacentre/factsheets/fs204/en [cited March 16, 2008]
  • Khokhar N, Gill ML, Malik GJ. General seroprevalence of hepatitis C and hepatitis B virus infections in population. J Coll Physicians Surg Pak. 2004;14:534–6. [PubMed]
  • Gaeta GB, Rapicetta M, Sardaro C, Spadaro A, Chionne F, Freni AM. Prevalence of anti-HCV antibodies in patients with chronic liver disease and its relationship to HBV and HDV infections. Infection. 1990;18:277–9. doi: 10.1007/BF01647003. [PubMed] [Cross Ref]
  • Tsatsralt-Od B, Takahashi M, Nishizawa T, Endo K, Inoue J, Okamoto H. High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. J Med Virol. 2005;77:491–9. doi: 10.1002/jmv.20482. [PubMed] [Cross Ref]
  • Fattovich G, Tagger A, Brollo L. Hepatitis C infection in chronic hepatitis B virus carriers. J Infect Dis. 1991;163:400–402. doi: 10.1093/infdis/163.2.400. [PubMed] [Cross Ref]
  • Alberti A, Pontisso P, Chemello L. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol. 1995;22:S38–S41. [PubMed]
  • Sheen IS, Liaw YF, Lin DY, Chu CM. Role of hepatitis C and Delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study. J Infect Dis. 1994;170:358–361. doi: 10.1093/infdis/170.2.358. [PubMed] [Cross Ref]
  • Rizzetto M, Verma G. J Hepatol. 1985. pp. 187–193. [PubMed] [Cross Ref]
  • Liu Z, Hou J. Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Int J Med Sci. 2006;3:57–62. [PMC free article] [PubMed]
  • Ganesh Kumar A, Sridharan K, Thirunalasundari T. Prevalence Pattern of Blood Borne Hepatitis Group of Viruses in Liver Disease Patients. World Journal of Medical Sciences. 2007;2(1):33–38.
  • Purcell RH. In: The hepatitis viruses: an overview. Viral Hepatitis and Liver Disease. Nishioka K, Suzuki H, Mishiro S and Oda T, editor. Springer Verlag, Tokyo, Japan; 1995.
  • Di Marco V, Lo Iacono O, Camma C, Vaccaro A, Giunta M, Martorana G. The long-term course of chronic hepatitis B. Hepatology. 1999;30:257–64. doi: 10.1002/hep.510300109. [PubMed] [Cross Ref]
  • Lihong W. Pathogenesis of hepatitis B virus infection. Future Virol. 2006;1:637–647. doi: 10.2217/17460794.1.5.637. [Cross Ref]
  • Rehermann B. Immune response in hepatitis B virus infection. Semin Liver, Dis. 2003;23:21–37. doi: 10.1055/s-2003-37586. [PubMed] [Cross Ref]
  • Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology. 2003;38:4–13. [PubMed]
  • Alter HJ. To C or not to C: these are the questions. Blood. 1995;85:1681–95. [PubMed]
  • Lok AS. Chronic hepatitis B. N Engl J Med. 2002;346:1682–3. doi: 10.1056/NEJM200205303462202. [PubMed] [Cross Ref]
  • Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107. doi: 10.1046/j.1365-2893.2003.00487.x. [PubMed] [Cross Ref]
  • Wright TL. Introduction to chronic hepatitis B infection. Am J Gastroenterol. 2006;101(Suppl 1):S1–6. [PubMed]
  • Korba BE, Gowans EJ, Wells FV, Tennant BC, Clarke R, Gerin JL. Systemic distribution of woodchuck hepatitis virus in the tissues of experimentally infected woodchucks. Virology. 1988;165:172–181. doi: 10.1016/0042-6822(88)90670-8. [PubMed] [Cross Ref]
  • Marion PL. Use of animal models to study hepatitis B viruses. Prog Med Virol. 1988;35:43–75. [PubMed]
  • Gish RG, Lau JYN. Hepatitis C virus: eight years old. Viral Hepatitis Reviews. 1997;1:17–37.
  • Alter MJ, Kruszon Moran D, Nainan OV. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562. doi: 10.1056/NEJM199908193410802. [PubMed] [Cross Ref]
  • Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43:1303–10. doi: 10.1002/hep.21176. [PubMed] [Cross Ref]
  • Ryu KJ, Lee SW. Comparative analysis of intracellular trans-splicing ribozyme Activity against hepatitis C virus internal ribosome entry site. J Microbiol. 2004;42:361–364. [PubMed]
  • Tagger A, Brollo L. Hepatitis C virus infection in chronichepatitis B virus carriers. J Infect Dis. 1991;163:400–402. doi: 10.1093/infdis/163.2.400. [PubMed] [Cross Ref]
  • Sato S, Fujiyama S, Tanaka M. Coinfection of hepatitis C virus in patientswith chronic hepatitis B infection. J Hepatol. 1994;21:159–166. doi: 10.1016/S0168-8278(05)80389-7. [PubMed] [Cross Ref]
  • Crespo J, Lozano JL, de la Cruz F. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol. 1994;89:147–1151. [PubMed]
  • Alberti A, Pontisso P, Chemello L. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol. 1995;22:38–41. [PubMed]
  • Zarski JP, Bohn B, Bastie A. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998;28:27–33. doi: 10.1016/S0168-8278(98)80198-0. [PubMed] [Cross Ref]
  • Rizzetto M, Verme G, Recchida S. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Annals of Internal Medicine. 1983;98:437–441. [PubMed]
  • Grosheide P, van Damme P. In: Communicable Diseases Series, 1 World Health Organization, Geneva. Hallauer J, Kane M, McCoy E, Meleus A and Mource C, editor. 1996. Prevention and control of hepatitis B in the community.
  • Hadziyannis SJ. In: Viral Hepatitis and Liver Disease. Rizzetto M, Purcell RH, Gerin JL and Verme G, editor. Edizioni Minerva Medica, Rome, Italy; 1997. Hepatitis delta: an overview; pp. 283–289.
  • Farci PF. Treatment of chronic hepatitis D: new advances, old challenges. Hepatology. 2006;44(3):536–539. doi: 10.1002/hep.21351. [PubMed] [Cross Ref]
  • Verme G, Brunetto MR, Oliveri F, Baldi M, Forzani B, Piantino P, Ponzetto A, Bonino F. Role of hepatitis delta virus infection in hepatocellular carcinoma. Dig Dis Sci. 1991;36:1134–1136. doi: 10.1007/BF01297460. [PubMed] [Cross Ref]
  • Oliveri F, Colombatto P, Derenzini M, Trere D, Papotti M, David E, Negro F, Bellati G, Ideo G, D'Aquino M, Michieletto L, Verme G, Bonino F, Brunetto MR. Hepatocellular carcinoma: Pathogenetic implications of the hepatitis delta virus. Prog Clin Biol Res. 1993;382:165–170. [PubMed]
  • Zuberi BF, Salahuddin A, Quraishy MS. Triple hepatitis: frequency and treatment outcome of co/super infection of hepatitis C and D among patient of hepatitis B. J Coll Physicians Surg Pak. 2008;18:404–407. [PubMed]
  • Zuberi BF, Quraishy MS, Afsar S, Kazi LA, Memon A, Qadeer R. Frequency and comparative analysis of hepatitis D in patients seeking treatment for hepatitis B. J Coll Physicians Surg Pak. 2006;16:581–4. [PubMed]
  • Kurbanov F, Tanaka Y, Elkady A, Oyunsuren T, Mizokami M. Tracing hepatitis C and Delta viruses to estimate their contribution in HCC rates in Mongolia. J Viral Hepat. 2007;14:667–74. doi: 10.1111/j.1365-2893.2007.00864.x. [PubMed] [Cross Ref]
  • Tsatsralt-Od B, Takahashi M, Nishizawa T, Inoue J, Ulaankhuu D, Okamoto H. High prevalence of hepatitis B, C and delta virus infections among blood donors in Mongolia. Arch Virol. 2005;150:2513–28. doi: 10.1007/s00705-005-0590-1. [PubMed] [Cross Ref]
  • Takahashi M, Nishizawa T, Gotanda Y, Tsuda F, Komatsu F, Kawabata T. High prevalence of antibodies to hepatitis A and E viruses and viremia of hepatitis B, C, and D viruses among apparently healthy populations in Mongolia. Clin Diagn Lab Immunol. 2004;11:392–8. [PMC free article] [PubMed]
  • Huang YH, Wu JC, Chau GY, Tsay SH, King KL, Sheng WY, Lui WY, Lee SD. Detection of serum hepatitis B, C, and D viral nucleic acids and its implications in hepatocellular carcinoma patients. J Gastroenterol. 1998;33(4):512–516. doi: 10.1007/s005350050124. [PubMed] [Cross Ref]
  • Radhakrishnan S, Abraham P, Raghuraman S, John GT, Thomas PP, Jacob CK, Sridharan G. Role of molecular techniques in the detection of HBV DNA & HCV RNA among renal transplant recipients in India. Indian J Med Res. 2000;111:204–11. [PubMed]
  • Gaeta GB, Precone DF, Cozzi-Lepri A. Multiple viral infections. J Hepatol. 2006;44:S108–S113. [PubMed]
  • MacDonald M, Crofts N, Kaldor J. Transmission of Hepatitis C Virus: Rates, Routes, and Cofactors. Epidemiologic Reviews. [PubMed]
  • Mathurin P, Thibault V, Kadidja K, Ganne-Carrie N, Moussalli J, El Younsi M. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J Viral Hepat. 2000;7:15–22. [PubMed]
  • Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology. 1995;22:1101–8. [PubMed]
  • Choo QL, Weiner AJ, Overby LR. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull. 1990;46:423–41. [PubMed]
  • Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis. C Hepatology. 2004;39(4):1147–71. doi: 10.1002/hep.20119. [PubMed] [Cross Ref]
  • Lavanchy D. Hepatitis B epidemiology, disease burden, treatment and current and emerging prevention and control measures. J Viral Hepat. 2004. pp. 97–107. [PubMed]
  • Juszczyk J. Clinical course and consequences of hepatitis B infection. Vaccine. 2000;18(supplement 1):S23–S25. [PubMed]
  • Kumar V, Das S, Jameel S. The biology and pathogenesis of hepatitis viruses. Current Science. 2010;98(3)
  • Xu R, Gan X, Fang Y, Zheng S, Dong Q. A simple, rapid and sensitive integrated protein microarray for simultaneous detection of multiple antigens and antibodies of five human hepatitis viruses (HBV, HCV, HDV, HEV, and HGV) Anal Biochem. 2007;362:69–75. doi: 10.1016/j.ab.2006.12.008. [PubMed] [Cross Ref]
  • Brotman B, Prince AM, Huima T, Richardson L, van den Ende MC, Pfeifer U. Interference between non-A, non-B and hepatitis B virus infection in chimpanzees. J Med Virol. 1983;11:191–205. doi: 10.1002/jmv.1890110303. [PubMed] [Cross Ref]
  • Eyster ME, Sanders JC, Battegay M, Di Bisceglie AM. Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C. Dig Dis Sci. 1995;40:1583–1588. doi: 10.1007/BF02285214. [PubMed] [Cross Ref]
  • Sagnelli E, Coppola N, Scolastico C, Filippini P, Santantonio T, Stroffolini T. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology. 2000;32:1106–1110. doi: 10.1053/jhep.2000.19288. [PubMed] [Cross Ref]
  • Jardi R, Rodriguez F, Buti M, Costa X, Cotrina M, Galimany R. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology. 2001;34:404–410. doi: 10.1053/jhep.2001.26511. [PubMed] [Cross Ref]
  • Wedemeyer H, Tillmann HL, Tegtmeyer B. Infection with multiple hepatitis viruses: evidence for suppression of HCVreplication byHDVand HBV. Hepatology. 2001;34:223. [PubMed]
  • Deterding K, Pothakamuri SV, Schlaphoff V. Clearance of Chronic HCV Infection During Acute D hepatitis. Infection. 2009;37:159–62. doi: 10.1007/s15010-007-7204-7. [PubMed] [Cross Ref]
  • Modahl LE, Lai MM. The large delta antigen of hepatitis delta virus potently inhibits genomic but not antigenomic RNA synthesis: a mechanism enabling initiation of viral replication. J Virol. 2000;74:7375–7380. doi: 10.1128/JVI.74.16.7375-7380.2000. [PMC free article] [PubMed] [Cross Ref]
  • Liaw Y-F, Tsai S-L, Sheen IS, Chao M, Yeh CT, Hsieh SY, Chu CM. Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. Am J Gastroenterol. 1998;93:354–359. doi: 10.1111/j.1572-0241.1998.00354.x. [PubMed] [Cross Ref]
  • Weltman MD, Brotodihardjo A, Crewe EB, Farrell GC, Bilous M, Grierson JM, Liddle C. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat. 1995;2(1):39–45. doi: 10.1111/j.1365-2893.1995.tb00070.x. [PubMed] [Cross Ref]
  • Gheorghe L, Iacob S, Simionov I, Vadan R, Gheorghe C, Iacob R. Natural history of compensated viral B and D cirrhosis. Rom J Gastroenterol. 2005;14:329–35. [PubMed]
  • Chu CM, Sheen IS, Liaw YF. The role of hepatitis C virus in fulminant viral hepatitis in an endemic area of hepatitis A and B. Gastroenterology. 1994;107:189–195. [PubMed]
  • Wu JC, Chen CL, Hou MC, Chen TZ, Lee SD, Lo KJ. Multiple viral infection as the most common cause of fulminant and sub-fulminant viral hepatitis in an area endemic for hepatitis B: application and limitation of the polymerase chain reaction. Hepatology. 1994;19:836–840. doi: 10.1002/hep.1840190406. [PubMed] [Cross Ref]
  • Crockett SD, Keeffe EB. Natural history and treatment of hepatitis B virus and hepatits C virus coinfection. Ann Clin Microbiol Antimicrob. 2005;4:13. doi: 10.1186/1476-0711-4-13. [PMC free article] [PubMed] [Cross Ref]
  • Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology. 2004;126:1024. doi: 10.1053/j.gastro.2004.01.011. [PubMed] [Cross Ref]
  • Fong TL, Di Bisceglie AM, Waggoner JG, Banks SM, Hoofnagle JH. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology. 1991;14:64–67. doi: 10.1002/hep.1840140111. [PubMed] [Cross Ref]
  • Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-co-infected patients. Hepatology. 2006;43:100–7. doi: 10.1002/hep.20944. [PubMed] [Cross Ref]
  • Lau DT, Doo E, Park Y, Kleiner DE, Schmid P, Kuhns MC. Lamivudine for chronic delta hepatitis. Hepatology. 1999;30:546–9. doi: 10.1002/hep.510300217. [PubMed] [Cross Ref]
  • Wolters LM, van Nunen AB, Honkoop P, Vossen AC, Niesters HG, Zondervan PE. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat. 2000;7:428–34. doi: 10.1046/j.1365-2893.2000.00254.x. [PubMed] [Cross Ref]
  • Taniguchi M, Shakil AO, Vargas HE, Laskus T, Demetris AJ, Gayowski T. Clinical and virologic outcomes of hepatitis B and C viral coinfection after liver transplantation: effect of viral hepatitis D. Liver Transpl. 2000;6:92–96. [PubMed]
  • Kane MA. Global status of hepatitis B Immunization. Lancet. 1996;348:696. [PubMed]

Articles from Virology Journal are provided here courtesy of BioMed Central